Evidence map›Paper›PMID 28504684›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2017

Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies.

Wenjun Zhang, Antony Hubbard, Tobin Jones, Adriana Racolta, Srabani Bhaumik, Nick Cummins, Liping Zhang, Karl Garsha, Frank Ventura, Mark R Lefever and 6 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. CD300EExperimental & molecular medicine · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Wenjun ZhangVentana Medical Systems, Tucson, AZ, USA.
Antony HubbardVentana Medical Systems, Tucson, AZ, USA.
Tobin JonesVentana Medical Systems, Tucson, AZ, USA.
Adriana RacoltaVentana Medical Systems, Tucson, AZ, USA.
Srabani BhaumikVentana Medical Systems, Tucson, AZ, USA.
Nick CumminsVentana Medical Systems, Tucson, AZ, USA.
Liping ZhangVentana Medical Systems, Tucson, AZ, USA.
Karl GarshaVentana Medical Systems, Tucson, AZ, USA.
Frank VenturaVentana Medical Systems, Tucson, AZ, USA.
Mark R LefeverVentana Medical Systems, Tucson, AZ, USA.
Zhenqiang LuVentana Medical Systems, Tucson, AZ, USA.
John K HurleyVentana Medical Systems, Tucson, AZ, USA.
William A DayVentana Medical Systems, Tucson, AZ, USA.
Lidija Pestic-DragovichVentana Medical Systems, Tucson, AZ, USA.
Larry E MorrisonVentana Medical Systems, Tucson, AZ, USA.
Lei TangVentana Medical Systems, Tucson, AZ, USA.
Ventana Research Corporation (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ability to simultaneously visualize the presence, abundance, location and functional state of many targets in cells and tissues has been described as a true next-generation approach in immunohistochemistry (IHC). A typical requirement for multiplex IHC (mIHC) is the use of different animal species for each primary (1°Ab) and secondary (2°Ab) antibody pair. Although 1°Abs from different species have been used with differently labeled species-specific 2°Abs, quite often the appropriate combination of antibodies is not available. More recently, sequential detection of multiple antigens using 1°Abs from the same species used a microwaving treatment between successive antigen detection cycles to elute previously bound 1°Ab/2°Ab complex and therefore to prevent the cross-reactivity of anti-species 2°Abs used in subsequent detection cycles. We present here a fully automated 1°Ab/2°Ab complex heat deactivation (HD) method on Ventana's BenchMark ULTRA slide stainer. This method is applied to detection using fluorophore-conjugated tyramide deposited on the tissue and takes advantage of the strong covalent bonding of the detection substrate to the tissue, preventing its elution in the HD process. The HD process was characterized for (1) effectiveness in preventing Ab cross-reactivity, (2) impact on the epitopes and (3) impact on the fluorophores. An automated 5-plex fluorescent IHC assay was further developed using the HD method and rabbit 1°Abs for CD3, CD8, CD20, CD68 and FoxP3 immune biomarkers in human tissue specimens. The fluorophores were carefully chosen and the narrow-band filters were designed to allow visualization of the staining under fluorescent microscope with minimal bleed through. The automated 5-plex fluorescent IHC assay achieved staining results comparable to the respective single-plex chromogenic IHC assays. This technology enables automated mIHC using unmodified 1°Abs from same species and the corresponding anti-species 2°Ab on a clinically established automated platform to ensure staining quality, reliability and reproducibility.

Indexed as

AmidesAntibodiesBreastFemaleFluorescent DyesHumansImage Processing, Computer-AssistedImmunohistochemistryNeoplasmsPalatine TonsilReproducibility of ResultsAmidesAntibodiesFluorescent Dyes

Identifiers

PMID28504684
OpenAlexW2615055042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.